US 12,371,750 B2
Genes and gene signatures for diagnosis and treatment of melanoma
Michael Bryan Warf, Salt Lake City, UT (US); Benjamin Roa, Salt Lake City, UT (US); Alexander Gutin, Salt Lake City, UT (US); and Darl Flake, Salt Lake City, UT (US)
Assigned to MYRIAD MYPATH, LLC, Salt Lake City, UT (US)
Filed by MYRIAD MYPATH, LLC, Salt Lake City, UT (US)
Filed on Oct. 25, 2023, as Appl. No. 18/493,935.
Application 18/493,935 is a continuation of application No. 17/325,644, filed on May 20, 2021, granted, now 11,834,719.
Application 17/325,644 is a continuation of application No. 14/205,965, filed on Mar. 12, 2014, granted, now 11,021,752, issued on Jun. 1, 2021.
Claims priority of provisional application 61/889,609, filed on Oct. 11, 2013.
Claims priority of provisional application 61/793,031, filed on Mar. 15, 2013.
Prior Publication US 2024/0200145 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); G16B 20/00 (2019.01)
CPC C12Q 1/6886 (2013.01) [G16B 20/00 (2019.02); C12Q 2600/158 (2013.01)] 14 Claims
 
1. A method for diagnosing and treating melanoma in a patient, the method comprising:
a) obtaining a tissue sample from the patient and measuring in the sample from the patient mRNA expression levels of a panel of genes comprising a three gene combination consisting of:
PRAME;
S100-related gene comprising S100A9, S100A7, S100A8, S100A12, or PI3; and immune gene comprising CXCL9, CCL5, CXCL10, IRF1, PTPN22, PTPRC, LCP2, SELL or CD38, wherein mRNA expression levels are normalized to one or more house-keeping genes;
b) calculating a combined score by weighting the measured mRNA expression levels of each gene from the panel of genes with a predefined coefficient, and combining the weighted expression levels of each gene from the panel of genes to provide the combined score;
c) classifying the sample as a malignant melanoma when the combined score exceeding a reference value;
d) diagnosing the patient with the combined score exceeding a reference value as having a malignant melanoma; and
e) administering to the patient diagnosed as having the malignant melanoma one or more treatments selected from excising the malignant melanoma, excising the malignant melanoma and a border of normal skin, reexcising the site of the sample to remove additional tissue, reexcising additional tissue surrounding a biopsy site, removal of a lymph node, lymph node dissection, chemotherapy, radiation therapy, biological therapy, immunotherapy, and targeted therapy.